Entera Bio Revenue and Competitors
Estimated Revenue & Valuation
- Entera Bio's estimated annual revenue is currently $3.6M per year.
- Entera Bio's estimated revenue per employee is $155,000
Employee Data
- Entera Bio has 23 Employees.
- Entera Bio grew their employee count by 0% last year.
Entera Bio's People
Name | Title | Email/Phone |
---|---|---|
1 | COO | Reveal Email/Phone |
2 | Head Clinical Operations | Reveal Email/Phone |
3 | Head BioPharmaceutics and BioAnalytics | Reveal Email/Phone |
4 | Production and R&D employee | Reveal Email/Phone |
5 | Assistant Controller | Reveal Email/Phone |
Entera Bio Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Entera Bio?
Entera Bio is a product-focused biotechnology company specializing in the oral delivery of large molecules and biologics. Entera Bio is currently conducting clinical trials on its proprietary technology which allows oral delivery of large molecules and biologics while enhancing their absorption in the GI tract. Entera Bio's technology addresses the two major problems of oral drug delivery of large molecule APIs (active pharmaceutical ingredients). Most large molecules cannot be administered orally as they are not readily absorbed by the gastrointestinal tract and are rapidly degraded by a myriad of enzymes and acids in the gastrointestinal tract. Entera's Proprietary Technologies Act Synergistically to Transport and Protect Large Molecules.
keywords:N/AN/A
Total Funding
23
Number of Employees
$3.6M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Entera Bio News
AbbVie; Entera Bio; GlaxoSmithKline; Roche; Sun Pharmaceutical; Takeda; Takeda Pharmaceutical; Teva Pharmaceuticals. Hypoparathyroidism...
Entera Bio posted earnings per share of ($0.43) in the same quarter last year, which indicates a positive year over year growth rate of 62.8%.
Entera is a leader in the development of orally delivered large molecule therapeutics for use in areas with significant unmet medical need where...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $3.8M | 23 | -32% | N/A |
#2 | $4.7M | 23 | 0% | N/A |
#3 | $2.3M | 23 | N/A | N/A |
#4 | $1.7M | 23 | N/A | N/A |
#5 | $2.3M | 23 | N/A | N/A |